Grant, Call number PAR-25-297
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health
- , Add deadline: choose a calendar
- United States
- Institution applies
- Pharmacology, Clinical Neurology and
About
A cooperative agreement supports preclinical and early clinical development of drug candidates aimed at preventing Alzheimer’s disease, slowing its progression or treating cognitive and behavioral symptoms. Eligible activities include pharmacology, efficacy studies, target-engagement biomarkers and early clinical development.
Topics
Eligibility
Covers: Supports preclinical and early clinical development, including phase I work.
The lead applicant must be an eligible US organization. Eligible non-US components of US organizations may participate.
Eligible organizations include universities, nonprofit research organizations and other categories specified in the announcement. The lead applicant must be an eligible US organization. Eligible non-US components of US organizations may participate.
Source: simpler.grants.gov